Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.62 |
| ▸ | CA2 | P00918 | 5/20 | 0.62 |
| ▸ | CA12 | O43570 | 4/20 | 0.62 |
| ▸ | CA7 | P43166 | 4/20 | 0.62 |
| ▸ | CA9 | Q16790 | 4/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.62 |
| ▸ | XDH | P47989 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30863575 | 1.00 | CA1 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8330557 | 0.91 | CA12 (0.53) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2427132 | 0.86 | CA1 (0.62) | CA1CA2CA12CA7CA9 | |
| SCHEMBL8148281 | 0.86 | CA1 (0.52) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28880690 | 0.84 | CA1 (0.50) | CA1CA2CA12CA7CA9 | |
| SCHEMBL4598114 | 0.83 | KDM4E (0.57) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2478176 | 0.83 | CA1 (0.49) | CA1CA2CA12CA7CA9 | |
| SCHEMBL338124 | 0.82 | CA12 (0.66) | CA1CA2CA12CA7CA9 | |
| SCHEMBL366584 | 0.81 | CA1 (0.47) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2483007 | 0.81 | NOTUM (0.50) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | RPXDS CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | BETTA PHARMACEUTICALS CO.,LTD (CN) | 2025-07-10 | — | — | US | disclosed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | disclosed |
| EP-4561975-A1 | FTO INHIBITORS | RPXDS Co., Ltd (CN) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025090792-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-05-01 | — | — | WO | disclosed |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | ARENA PHARMACEUTICALS, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| CN-113365995-B | Immunomodulators, compositions and methods thereof | 贝达药业股份有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119546566-A | FTO inhibitors | 瑞璞鑫(苏州)生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | BETTA PHARMACEUTICALS CO., LTD (CN) | 2025-01-07 | — | — | US | disclosed |
| WO-2024199421-A1 | CYP11A1 INHIBITOR | 山东轩竹医药科技有限公司 | 2024-10-03 | — | — | WO | disclosed |
| US-6077853-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 2000-06-20 | — | — | US | disclosed |
| EP-0994848-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-04-26 | — | — | EP | disclosed |
| EP-0594019-B1 | 1-Biphenylmethyl-pyridone derivatives, their preparation and their use as angiotensin II antagonistes | BAYER AG (DE) | 2000-02-23 | — | — | EP | disclosed |
| EP-0951285-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-10-27 | — | — | EP | disclosed |
| US-5939439-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-08-17 | — | — | US | disclosed |
| US-5863930-A | ATHEROSCLEROSIS TREATMENT FORMED BY REACTION OF PYRIDONES WITH BIPHENYLMETHYL HALOGEN | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-26 | — | — | US | disclosed |
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |
| WO-1998029119-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5596006-A | ANTIHYPERTENSIVE, ANTIATHEROSCLEROTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-01-21 | — | — | US | disclosed |
| EP-0594019-A1 | Trisubstituted biphenyl as angiotensin II antagonistes | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260035341-A1 | FTO INHIBITORS | FTO, LDLR, GPR119 | CA1 3210/4885CA2 3929/4885CA12 4386/4885 |
| US-20250223286-A1 | IMMUNOMODULATORS, COMPOSITIONS AND METHODS THEREOF | IL2, IL5, TSLP | CA1 2975/4885CA2 3614/4885CA12 928/4885 |
| US-12187713-B2 | Immunomodulators, compositions and methods thereof | IL2, TSLP, CD74 | CA1 4067/4885CA2 4414/4885CA12 1576/4885 |
| US-20250074874-A1 | SUBSTITUTED (1,2,3,4-TETRAHYDROCYCLOPENTA[b]INDOL-3-YL)ACETIC ACID DERIVATIVES USEFUL IN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS | S1PR1, S1PR3, S1PR2 | CA1 2926/4885CA2 3007/4885CA12 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.